NanoViricides Inc. (NNVC)

[JG36]

The "diversion" is done by charging excessive prices for licensing and leasing deals, when NNVC is in no position to refuse.

Again, the efficacy of nanoviricides are irrelevant to the claims in the suit, so claims about how many rodents have been cured of this or that disease are beside the point.

The truth is that the relationship between Theracour and NNVC has long been one of the most problematic issues for this stock. Most start up biotechs at least own their core intellectual property. NNVC does not, it purchases licenses to the IP from Theracour.